Skip to main content

Table 1 Clinical features of patient samples used in the present study

From: SHP1 and SHP2 inhibition enhances the pro-differentiative effect of phorbol esters: an alternative approach against acute myeloid leukemia

ID Age (years) FAB subtype Karyotype Mutations
AML1 53 M0 46, XX, t(3;3)(q21;q21) [20] WT1
IDH1
AML2 59 M0 46, XY N/D
AML3 57 M0 46, XY N/A
AML4 52 M1 45, XX, −7 [15] N/D
AML5 71 M0 46, XX, del (5q)(q13q35) [13]
47, XXSL, + 8 [2]
N/A
AML6 39 M4 46, XY FLT3
AML7 50 Secondary AML No metaphases N/D
AML8 64 M5 No metaphases NPM1
  1. Legend: N/A: not available, N/D: not detected, FAB: French-American-British classification